Levee Medical Inc. Company Profile

Background

Overview

Levee Medical Inc. is a medical device company headquartered in Durham, North Carolina, dedicated to enhancing recovery outcomes for patients undergoing prostate cancer surgery. The company's flagship product, the Voro® Urologic Scaffold, is an absorbable device designed to mitigate post-prostatectomy stress urinary incontinence. This innovative solution aims to support the bladder neck and maintain urethral length during prostatectomy procedures, thereby reducing the incidence of incontinence following surgery.

Mission and Vision

Levee Medical's mission is to develop and commercialize medical devices that address significant unmet needs in urological health, particularly focusing on improving the quality of life for prostate cancer survivors. The company's vision is to become a leader in urological device innovation, providing solutions that enhance patient outcomes and set new standards in surgical recovery.

Industry Significance

The prevalence of prostate cancer and the associated risk of post-surgical incontinence present a substantial challenge in urological healthcare. Levee Medical's focus on developing the Voro® Urologic Scaffold positions the company at the forefront of addressing these challenges, offering a promising solution that could transform post-operative care and significantly improve patient quality of life.

Key Strategic Focus

Core Objectives

Levee Medical is committed to advancing the development of the Voro® Urologic Scaffold, aiming to:

Demonstrate the safety and efficacy of the device through rigorous clinical trials.

Obtain regulatory approvals for commercialization in key markets.

Establish strategic partnerships to facilitate widespread adoption and distribution.

Areas of Specialization

The company specializes in the design, development, and manufacturing of bioresorbable urological devices, with a primary focus on:

Innovative solutions for post-prostatectomy stress urinary incontinence.

Minimally invasive surgical interventions.

Patient-centric medical device development.

Key Technologies Utilized

Levee Medical employs advanced biomaterials and engineering techniques to create the Voro® Urologic Scaffold, ensuring:

Biocompatibility and bioresorbability.

Structural support for the bladder neck and urethra.

Integration with human tissue to promote natural healing processes.

Primary Markets Targeted

The company's primary market focus includes:

Urological surgical centers.

Hospitals and clinics specializing in prostate cancer treatment.

Healthcare providers involved in post-operative care and rehabilitation.

Financials and Funding

Total Funds Raised

Levee Medical has successfully raised a total of $34.2 million over multiple funding rounds, reflecting strong investor confidence in its innovative approach to addressing post-prostatectomy complications.

Recent Funding Rounds

Series B Financing (February 2025): The company secured over $14 million, including note conversions, to accelerate the development of the Voro® Urologic Scaffold and support ongoing clinical studies.

Series A Financing (August 2022): Levee Medical closed an oversubscribed Series A round, raising $6.6 million to advance product development and scale infrastructure.

Notable Investors

While specific investor identities are not publicly disclosed, the substantial funding and strategic investments indicate strong backing from venture capital firms and private investors interested in medical device innovation.

Utilization of Capital

The raised funds are allocated towards:

Advancing the development and manufacturing of the Voro® Urologic Scaffold.

Conducting and expanding clinical trials to validate device safety and efficacy.

Regulatory submissions and approvals for commercialization.

Scaling operational capabilities to support market entry and distribution.

Pipeline Development

Key Pipeline Candidates

Voro® Urologic Scaffold: The primary product in development, designed to reduce post-prostatectomy stress urinary incontinence by supporting the bladder neck and maintaining urethral length during surgery.

Stages of Clinical Trials

ARID II Pivotal Trial: A multicenter, single-blind, randomized controlled study approved by the FDA, aiming to demonstrate the safety and effectiveness of the Voro® Urologic Scaffold in adult men undergoing robotic-assisted radical prostatectomy.

Target Conditions

Post-prostatectomy stress urinary incontinence.

Anticipated Milestones

First Patient Enrollment: Completed in April 2025, marking the initiation of the ARID II trial.

Regulatory Approvals: Ongoing efforts to obtain FDA clearance and approvals in other key markets.

Technological Platform and Innovation

Proprietary Technologies

Bioresorbable Materials: Utilizing advanced biomaterials that naturally degrade within the body, eliminating the need for surgical removal.

Surgical Integration: Designing the scaffold to seamlessly integrate with human tissue, promoting natural healing and reducing the risk of complications.

Significant Scientific Methods

Clinical Trials: Conducting rigorous, multicenter studies to gather comprehensive data on device performance and patient outcomes.

Regulatory Strategy: Implementing a strategic approach to navigate the regulatory landscape, ensuring compliance and expediting time-to-market.

Leadership Team

Key Executives

Adam Irving: Chief Executive Officer (CEO).

Professional Background: Extensive experience in medical device development and commercialization.

Contributions: Leading the company's strategic vision and overseeing operational execution.

Bruce Choi: Founder, Chief Technology Officer (CTO), and Chairman.

Professional Background: Background in biomedical engineering and medical device innovation.

Contributions: Driving technological development and ensuring product quality and safety.

Recent Leadership Changes

Tessa Yamut: Appointed Executive Vice President of Clinical and Regulatory Affairs in September 2023.

Professional Background: Nearly 30 years in the medical device industry, with 24 years in senior management roles.

Contributions: Enhancing the company's clinical and regulatory strategies to expedite product development and approval processes.

Competitor Profile

Market Insights and Dynamics

The urological device market, particularly concerning post-prostatectomy incontinence, is characterized by a significant unmet need for effective solutions. The market is expected to grow steadily, driven by increasing prostate cancer incidence and a focus on improving patient quality of life.

Competitor Analysis

UroCure: Develops minimally invasive devices for urological conditions, focusing on incontinence treatments.

PathRight Medical: Specializes in surgical solutions for urological diseases, including incontinence management.

Caldera Medical: Offers a range of urological implants and devices, with a focus on women's health but expanding into men's health.

Strategic Collaborations and Partnerships

Levee Medical has established collaborations with leading medical institutions to advance clinical research and trials, including partnerships with Johns Hopkins Medicine for the ARID II trial.

Operational Insights

Levee Medical differentiates itself through its focus on bioresorbable materials and patient-centric design, aiming to reduce the need for additional surgeries and improve post-operative recovery times.

Strategic Opportunities and Future Directions

The company plans to expand its product portfolio to address other urological conditions, leveraging its expertise in bioresorbable technology. Additionally, Levee Medical aims to enter international markets, capitalizing on the global demand for innovative urological solutions.